Evidence map›Paper›PMID 37605005›Full record

ArticleScientific reports2023

Amyloid-β slows cilia movement along the ventricle, impairs fluid flow, and exacerbates its neurotoxicity in explant culture.

Ryota Makibatake, Sora Oda, Yoshiki Yagi, Hitoshi Tatsumi

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.7field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Article
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Ryota MakibatakeDepartment of Applied Bioscience, Kanazawa Institute of Technology, Hakusan-shi, Ishikawa, 924-0838, Japan.
Sora OdaDepartment of Applied Bioscience, Kanazawa Institute of Technology, Hakusan-shi, Ishikawa, 924-0838, Japan.
Yoshiki YagiDepartment of Applied Bioscience, Kanazawa Institute of Technology, Hakusan-shi, Ishikawa, 924-0838, Japan.
Hitoshi TatsumiDepartment of Applied Bioscience, Kanazawa Institute of Technology, Hakusan-shi, Ishikawa, 924-0838, Japan. tatsumi@neptune.kanazawa-it.ac.jp.
Kanazawa Institute of Technology · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Alzheimer's disease (AD) is characterized by extensive and selective death of neurons and deterioration of synapses and circuits in the brain. The Aβ1-42 concentration is higher in an AD brain than in cognitively normal elderly individuals, and Aβ1-42 exhibits neurotoxicity. Brain-derived Aβ is transported into the cerebrospinal fluid (CSF), and CSF flow is driven in part by the beating of cilia and CSF secretion into ventricles. Ventricles are lined with ependyma whose apical surface is covered with motile cilia. Herein, we constructed an experimental system to measure the movement of ependymal cilia and examined the effects of Aβ1-42 to the beating of cilia and neurons. The circadian rhythm of the beating frequency of ependymal cilia was detected using brain wall explant-cultures containing ependymal cilia and neurons; the beating frequency was high at midday and low at midnight. Aβ1-42 decreased the peak frequency of ciliary beating at midday and slightly increased it at midnight. Aβ1-42 exhibited neurotoxicity to neurons on the non-ciliated side of the explant culture, while the neurotoxicity was less evident in neurons on the ciliated side. The neurotoxic effect of Aβ1-42 was diminished when 1 mPa of shear stress was generated using a flow chamber system that mimicked the flow by cilia. These results indicate that Aβ1-42 affects the circadian rhythm of ciliary beating, decreases the medium flow by the cilia-beating, and enhances the neurotoxic action of Aβ1-42 in the brain explant culture.

Indexed as

Alzheimer DiseaseNeurotoxicity SyndromesAgedAmyloid beta-PeptidesBrainCerebral VentriclesCiliaEpendymaHumansAmyloid beta-Peptides

Identifiers

PMID37605005
PMCPMC10442439
OpenAlexW4386027880

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.